Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

This study has been completed.

Study NCT00027690 Information provided by National Cancer Institute (NCI)

First Received: December 7, 2001 Last Updated: September 30, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	September 2011 (Final data collection date for primary outcome measure)

Publications:

Leslie KK, Sill MW, Darcy KM, et al.: Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. [Abstract] J Clin Oncol 27 (Suppl 15): A-e16542, 2009.